5qHZ6pi1Eho https://histock.tw/talk/live.aspx?name=gtalk&id=1327 20250507 阿布波

台股 » 個股 » 浩鼎 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

浩鼎

(4174)
可現股當沖
  • 股價
    39.20
  • 漲跌
    ▲1.05
  • 漲幅
    +2.75%
  • 成交量
    866
  • 產業
    上櫃 生技醫療類股
  • 227人加入追蹤

    立即追蹤

  • 本地時間:13:35(已收盤)

     
浩鼎 (4174)籌碼相關-永豐金-竹北 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

Created with Highstock 1.3.7Zoom券商分點個股進出嗨投資 histock.tw06/0106/1406/2807/1207/2608/1008/2409/0609/2010/0410/1811/0211/1611/3012/1412/2801/1001/2202/1402/2803/1203/2204/0104/1404/2405/063040506070Jul '24Sep '24Nov '24Jan '25Mar '25May '2560d90dAll

永豐金-竹北 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/05/0600.00238.5039.20-21,093-0.18%
2025/05/05237.93138.0038.1511,0850.09%
2025/05/02340.30140.9039.7521,0680.19%
2025/04/3000.001040.2539.40-101,044-0.96%
2025/04/291039.391239.6639.60-21,014-0.20%
2025/04/28236.65236.8037.0509360.00%
2025/04/25438.0000.0038.0047720.52%
2025/04/1400.00148.3048.20-1753-0.13%
2025/04/1100.00246.5346.90-2747-0.27%
2025/04/10450.35250.1050.1027280.27%
2025/04/0900.001148.0346.10-11709-1.55%
2025/04/08450.95250.9051.2026960.29%
2025/04/02162.8000.0062.0016710.15%
2025/04/0100.00959.8460.10-9663-1.36%
2025/03/31258.8000.0058.4026620.30%
2025/03/27061.7000.0061.2006600.00%
2025/03/26061.5000.0061.9006670.00%
2025/03/25161.3000.0061.1016700.15%
2025/03/215.462.3100.0062.805.46660.81%
2025/03/200.562.5000.0062.400.56520.08%
2025/03/14057.6000.0058.5006140.00%
2025/03/11356.6000.0057.2036300.48%
2025/03/07158.0000.0057.7016330.16%
2025/03/03159.0000.0058.5016290.16%
2025/02/24060.7000.0060.1006330.00%
2025/02/19158.7000.0058.7016310.16%
2025/02/18159.1000.0058.7016710.15%
2025/02/17060.2000.0060.1006710.00%
2025/02/14260.0500.0060.1026650.30%
2025/02/11059.8000.0059.1006790.00%
2025/02/10159.7000.0059.7016920.14%
2025/02/07161.3000.0061.7017030.14%
2025/02/06360.2700.0062.0037100.42%
2025/02/04159.0000.0058.9017260.14%
2024/12/24158.1000.0057.7011,1120.09%
2024/12/19158.30858.8058.30-71,216-0.58%
2024/12/162058.8000.0058.20201,2641.58%
2024/12/0300.00162.8063.00-11,369-0.07%
2024/11/26262.6000.0062.9021,6750.12%
2024/11/1900.00163.5063.50-12,150-0.05%
2024/11/1800.00163.4062.70-12,326-0.04%
2024/11/15162.7000.0061.8012,3500.04%
2024/11/14161.5000.0061.3012,3880.04%
2024/11/08163.5000.0063.5012,6520.04%
2024/11/07165.50265.6064.70-12,825-0.04%
2024/10/24166.8000.0066.8013,0360.03%
2024/10/23267.2000.0067.2023,0230.07%
2024/10/21167.4000.0067.8013,0240.03%
2024/10/18167.30268.5566.80-13,023-0.03%
2024/10/1700.00167.5067.00-13,005-0.03%
2024/10/15266.55166.9066.6013,0060.03%
2024/10/07174.0000.0074.1012,9530.03%
2024/10/04175.0000.0074.7012,9900.03%
2024/09/30376.2000.0076.0032,8590.10%
2024/09/2700.00173.7072.80-12,818-0.04%
2024/09/26375.1300.0073.4032,8140.11%
2024/09/2500.00278.1076.70-22,792-0.07%
2024/09/24272.6000.0072.8022,7070.07%
2024/09/2300.00275.4574.10-22,687-0.07%
2024/09/1800.00476.4076.60-42,648-0.15%
2024/09/05280.0500.0077.2022,5460.08%
2024/09/041079.0000.0078.90102,5360.39%
2024/09/022085.105483.9784.20-342,487-1.37%
2024/08/30187.80589.5088.00-42,435-0.16%
2024/08/291391.191190.8490.6022,3820.08%
2024/08/28689.28490.2390.0022,2870.09%
2024/08/27085.3000.0084.3002,1760.00%
2024/08/261088.80287.5086.3082,1240.38%
2024/08/23289.30188.8088.6012,0730.05%
2024/08/22389.90191.7989.8021,9840.10%
2024/08/21186.51188.4088.9001,8590.00%
2024/08/201384.22184.3885.90121,6640.72%
2024/08/16278.15179.4078.5011,4360.07%
2024/08/14076.4200.0075.9001,3150.00%
2024/08/13478.03177.4075.7031,2500.24%
2024/08/093177.1700.0074.80311,0422.98%
2024/08/08369.10470.6370.70-1844-0.12%
2024/08/0700.002564.6264.30-25771-3.24%
2024/08/061164.551062.5560.6017350.14%
2024/08/051063.651162.9561.60-1671-0.15%
2024/07/19164.00163.9062.6004880.00%
2024/07/16163.7000.0063.3014510.22%
2024/07/09562.3000.0062.6054261.17%
2024/06/24561.0000.0060.7053381.48%
2024/06/211061.0300.0061.00103412.93%
2024/06/1300.000.360.3060.20-0.3338-0.09%
2024/06/12160.5000.0060.0013410.29%
2024/05/1700.00161.3061.40-1399-0.25%
浩鼎ADC新藥獲FDA核准 將展開1/2期臨床試驗Anue鉅亨-4天前
〈熱門股〉浩鼎乳癌新藥解盲失利臨床喊卡 慘吞兩根跌停周跌近2成Anue鉅亨-10天前
〈焦點股〉浩鼎乳癌藥OBI-822臨床試驗喊卡 跳空跌停股價創新低Anue鉅亨-12天前
浩鼎 相關文章